« Previous
Next »
Titles
- Cost savings2
- Biologics in perspective: the case for generic biologic drugs1
- Competitive bidding in drug procurement: evidence from China1
- Congreso Internacional de Derecho y Economia Farmaceutica1
- Drug discount program: federal oversight of compliance at 340B contract pharmacies needs improvement : report to Congressional requesters1
- Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives1
- Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate1
- Drug discount program: update on agency efforts to improve 340B program oversight : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives1
- Drug price moderation in Germany: lessons for U.S. reform efforts1
- Equilibrium effects of pharmaceutical bundling: evidence from India1
- Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit1
- Medicaid's most costly outpatient drugs1
- Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices1
- Medicare Part D1
- Navigating the pharmacy benefits marketplace1
- One percent of drugs with Medicaid reimbursement were not FDA-approved1
- Prescription Drug User Fee Act waivers, reductions, and refunds for drug and biological products1
- Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers1
- Research and development in the pharmaceutical industry1
- Snapshots of recent state initiatives in Medicaid prescription drug cost control1